News | EU Patents Matter

World IP Day 2021: Biotech investors must open their mind to different IP strategies22 Apr 2021
Investors considering whether to put their capital into a biotech company will inevitably want to consider a target’s intellectual property (IP) strategy before doing so.
Paris Court orders a preliminary injunction against Zentiva over generic pemetrexed12 Apr 2021
Generic medicines manufacturer Zentiva is to pay €4 million in provisional damages after the Paris Judiciary Court ruled that the company was likely to have infringed a patent owned by originator Eli Lilly for its lung cancer treatment Alimta.
Patent ruling highlights need for legal basis for FRAND claims30 Mar 2021
Businesses need to be specific about the legal basis on which they are raising claims that the licensing terms proposed to them for using standard-essential patents (SEPs) are not fair, reasonable or non-discriminatory (FRAND) if they want their case to be heard by the courts in England and Wales, a...
UK patent and copyright law reform considered for AI age25 Mar 2021
Reforms to UK patent and copyright law could be tabled later this year to account for the growing use of artificial intelligence (AI) systems, the UK's Intellectual Property Office (IPO) has confirmed.
How a three-pronged IP strategy could help biosimilar manufacturers23 Mar 2021
Biosimilar manufacturers should assess the patent portfolios of third parties, determine whether they can obtain patent protection of their own, and identify opportunities for licensing, to take advantage of the opportunities for growth in the market in the years ahead.
The future of standard essential patent licensing9 Mar 2021
The law on standard essential patent (SEP) licensing has been heavily shaped by courts around the world in what is an increasingly global battleground over rights to use standardised communication technologies. It is expected to evolve further in 2021.